A. Zangrando

发表

Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks

D. Basso, S. Bicciato, G. Basso, 2009, Genes, chromosomes & cancer.

An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer

Igor Jurisica, Chiara Pastrello, Flavio Rizzolio, 2015, Oncotarget.

Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways.

H. Kestler, M. Schrappe, G. Basso, 2011, Cancer cell.

Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flow cytometric detection of minimal residual disease

S. Larin, B. Buldini, A. Zangrando, 2021, British journal of haematology.

Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.

Franco Locatelli, Giuseppe Basso, G. Basso, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia

M. Valsecchi, G. Basso, M. Putti, 2019, Leukemia & lymphoma.

Terdentate RuX(CNN)(PP) (X = Cl, H, OR) Complexes: Synthesis, Properties, and Catalytic Activity in Fast Transfer Hydrogenation

A. Zangrando, A. D. Zotto, P. Rigo, 2006 .

Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia

G. Basso, A. Biondi, B. Buldini, 2010, American journal of hematology.

Acute Lymphoid Leukaemias (ALL) and Minimal Residual Disease in ALL

G. Basso, B. Buldini, A. Zangrando, 2018 .

A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients

I. Jurisica, A. Giordano, M. Agostini, 2015, Cancer biology & therapy.

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures

Giuseppe Basso, G. Basso, A. Zangrando, 2009, BMC Medical Genomics.

MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study

F. Locatelli, G. Basso, G. Kronnie, 2011, Leukemia.

New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures

Giuseppe Basso, Alexander Kohlmann, A. Kohlmann, 2006, BMC Genomics.

Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia.

G. Basso, M. Pigazzi, A. Zangrando, 2006, Haematologica.

CD56, HLA‐DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3‐GLIS2 fusion transcript

G. Basso, A. Pession, F. Locatelli, 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer.

I. Jurisica, S. Bortoluzzi, A. Giordano, 2015, Oncotarget.

Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study

G. Kronnie, F. Intini, A. Zangrando, 2008, Leukemia.

Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways.

H. Kestler, M. Schrappe, G. Basso, 2011, Cancer cell.